missing translation for 'onlineSavingsMsg'
Learn More

LGC Genomics Llc (Lucigen) ClearColi BL21(DE3) Electrocompetent Cells, 12 Rxns (DUOs)Eliminate endotoxin at the source with this unique engineered E. coli strain for low-endotoxin protein expression.

Numéro de catalogue. NC0487614
Encompass

ClearColi BL21(DE3) cells are the first commercially available competent cells with a modified LPS that does not trigger the endotoxic response in mammalian cells. ClearColi™ cells lack outer membrane agonists for hTLR4/MD-2 activation; therefore, activation of hTLR4/MD-2 signalling by ClearColi is several orders of magnitude lower compared with E. coli wild-type cells, and heterologous proteins prepared from ClearColi are virtually free of endotoxic activity. After minimal purification from ClearColi cells, proteins or plasmids, which may still contain Lipid IVA, can still be used in most applications without eliciting an endotoxic response.

Numéro de catalogue. NC0487614 Fournisseur LGC Genomics Llc Code fournisseur 608101

Pour de l'aide SVP utiliser la function de clavardage; nous envoyer un couriel à help@thermofisher.com ou appelez le service à la clientèle au 1-800-234-7437.

ClearColi BL21(DE3) cells are the first commercially available competent cells with a modified LPS that does not trigger the endotoxic response in mammalian cells. ClearColi™ cells lack outer membrane agonists for hTLR4/MD-2 activation; therefore, activation of hTLR4/MD-2 signalling by ClearColi is several orders of magnitude lower compared with E. coli wild-type cells, and heterologous proteins prepared from ClearColi are virtually free of endotoxic activity. After minimal purification from ClearColi cells, proteins or plasmids, which may still contain Lipid IVA, can still be used in most applications without eliciting an endotoxic response.